Strategic Partners OneOme’s RightMed pharmacogenomics solutions paired with an in-house CLIA-certified, CAP-accredited lab position the company as a valuable partner for healthcare systems seeking integrated genetics-enabled prescribing. Potential sales opportunity: collaborate with large health systems and hospital networks to embed pharmacogenomic testing into standard of care, expanding adoption through payer contracts and value-based care programs.

Payer Alignment The RightMed offering is described as reducing costs through personalized prescriptions, signaling strong payer interest. Potential sales opportunity: target health plans and pharmacy benefit managers to integrate pharmacogenomic insights into formulary decisions, supporting cost containment and improved outcomes while creating scalable reimbursement pathways.

Expansion Readiness Recent news indicates asset sale to Tempus in 2025, suggesting a market consolidation dynamic and potential access to pharmacogenetics assets through strategic partners. Potential sales opportunity: pursue co-selling or white-label arrangements with analytics and tech-focused healthcare companies to accelerate market reach and leverage enhanced data capabilities.

Clinical Adoption With leadership and lab operations oriented toward clinical integration, OneOme serves doctors, pharmacists, and healthcare providers. Potential sales opportunity: target multistate health systems and academic medical centers with pilot programs demonstrating improved medication outcomes, then scale via centralized ordering platforms and clinician education programs.

Technology Stack A diverse tech stack including AWS, Salesforce, and marketing cloud tools indicates readiness for enterprise deployments and CRM-driven outreach. Potential sales opportunity: offer scalable deployment alongside existing informatics infrastructure, enabling seamless data exchange with EHRs and enabling outcome tracking, payer analytics, and targeted provider engagement campaigns.